297 related articles for article (PubMed ID: 17398372)
1. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.
Heart Protection Study Collaborative Group
J Vasc Surg; 2007 Apr; 45(4):645-654; discussion 653-4. PubMed ID: 17398372
[TBL] [Abstract][Full Text] [Related]
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Heart Protection Study Collaborative Group
Lancet; 2002 Jul; 360(9326):7-22. PubMed ID: 12114036
[TBL] [Abstract][Full Text] [Related]
3. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
Collins R; Armitage J; Parish S; Sleigh P; Peto R;
Lancet; 2003 Jun; 361(9374):2005-16. PubMed ID: 12814710
[TBL] [Abstract][Full Text] [Related]
4. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
Collins R; Armitage J; Parish S; Sleight P; Peto R;
Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
[TBL] [Abstract][Full Text] [Related]
5. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
Heart Protection Study Collaborative Group
Lancet; 2011 Dec; 378(9808):2013-2020. PubMed ID: 22115874
[TBL] [Abstract][Full Text] [Related]
6. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.
Eur Heart J; 1999 May; 20(10):725-41. PubMed ID: 10329064
[TBL] [Abstract][Full Text] [Related]
7. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Baigent C; Landray MJ; Reith C; Emberson J; Wheeler DC; Tomson C; Wanner C; Krane V; Cass A; Craig J; Neal B; Jiang L; Hooi LS; Levin A; Agodoa L; Gaziano M; Kasiske B; Walker R; Massy ZA; Feldt-Rasmussen B; Krairittichai U; Ophascharoensuk V; Fellström B; Holdaas H; Tesar V; Wiecek A; Grobbee D; de Zeeuw D; Grönhagen-Riska C; Dasgupta T; Lewis D; Herrington W; Mafham M; Majoni W; Wallendszus K; Grimm R; Pedersen T; Tobert J; Armitage J; Baxter A; Bray C; Chen Y; Chen Z; Hill M; Knott C; Parish S; Simpson D; Sleight P; Young A; Collins R;
Lancet; 2011 Jun; 377(9784):2181-92. PubMed ID: 21663949
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study.
; Jonathan Emberson ; Derrick Bennett ; Emma Link ; Sarah Parish ; John Danesh ; Jane Armitage ; Rory Collins
Lancet; 2011 Feb; 377(9764):469-76. PubMed ID: 21277016
[TBL] [Abstract][Full Text] [Related]
9. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
; Armitage J; Bowman L; Wallendszus K; Bulbulia R; Rahimi K; Haynes R; Parish S; Peto R; Collins R
Lancet; 2010 Nov; 376(9753):1658-69. PubMed ID: 21067805
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
[TBL] [Abstract][Full Text] [Related]
11. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
; Mihaylova B; Emberson J; Blackwell L; Keech A; Simes J; Barnes EH; Voysey M; Gray A; Collins R; Baigent C
Lancet; 2012 Aug; 380(9841):581-90. PubMed ID: 22607822
[TBL] [Abstract][Full Text] [Related]
12. Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R; Reith C; Emberson J; Armitage J; Baigent C; Blackwell L; Blumenthal R; Danesh J; Smith GD; DeMets D; Evans S; Law M; MacMahon S; Martin S; Neal B; Poulter N; Preiss D; Ridker P; Roberts I; Rodgers A; Sandercock P; Schulz K; Sever P; Simes J; Smeeth L; Wald N; Yusuf S; Peto R
Lancet; 2016 Nov; 388(10059):2532-2561. PubMed ID: 27616593
[TBL] [Abstract][Full Text] [Related]
13. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Baigent C; Landray M; Leaper C; Altmann P; Armitage J; Baxter A; Cairns HS; Collins R; Foley RN; Frighi V; Kourellias K; Ratcliffe PJ; Rogerson M; Scoble JE; Tomson CR; Warwick G; Wheeler DC
Am J Kidney Dis; 2005 Mar; 45(3):473-84. PubMed ID: 15754269
[TBL] [Abstract][Full Text] [Related]
14. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].
Heart Protection Study Collaborative Group
BMC Med; 2005 Mar; 3():6. PubMed ID: 15771782
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Baigent C; Keech A; Kearney PM; Blackwell L; Buck G; Pollicino C; Kirby A; Sourjina T; Peto R; Collins R; Simes R;
Lancet; 2005 Oct; 366(9493):1267-78. PubMed ID: 16214597
[TBL] [Abstract][Full Text] [Related]
16. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
Storey BC; Staplin N; Haynes R; Reith C; Emberson J; Herrington WG; Wheeler DC; Walker R; Fellström B; Wanner C; Landray MJ; Baigent C;
Kidney Int; 2018 Apr; 93(4):1000-1007. PubMed ID: 29146277
[TBL] [Abstract][Full Text] [Related]
17. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
18. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Sharp Collaborative Group
Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R;
Lancet; 2005 May 21-27; 365(9473):1779-85. PubMed ID: 15910950
[TBL] [Abstract][Full Text] [Related]
20. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
Stoekenbroek RM; Boekholdt SM; Fayyad R; Laskey R; Tikkanen MJ; Pedersen TR; Hovingh GK;
Heart; 2015 Mar; 101(5):356-62. PubMed ID: 25595417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
